SKLB-03220 is a novel EZH2 covalent inhibitor, exerts potent anti-tumor activity in ovarian cancer

Yongxia Zhu, Xinyi Chen, Qiangsheng Zhang, Lihong Shi, Luoting Yu, Hongtao Xiao

Department of Clinical Pharmacy, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610041, China.
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, China

Introduction

Enhancer of Zeste Homolog 2 (EZH2) is the catalytic subunit of the Polycomb Repressive Complex 2 (PRC2) that regulate downstream target genes expression, and then promotes tumor cell proliferation, metastasis and drug resistance. EZH2 also performs some functions in a PRC2-independent manner. Most of reported EZH2 inhibitors are S-adenosyl-methionine (SAM)-competitive inhibitor, and are less selective for EZH2 close homolog EZH1, which resulted in safety concerns and insufficient efficacy. To obtain irreversible EZH2 inhibitor, a novel covalent inhibitor was developed and characterized.

Methods

SKLB-03220 and its derivatives were designed, synthesized and confirmed as EZH2 covalent inhibitor by us. The mechanism of covalent binding of SKLB-03220 was confirmed by SAM competition experiments, mass spectrometry, and washing-out assays. Furthermore, the anti-tumor activities of SKLB-03220 in ovarian cancer were investigated by MTT assay, colony formation assay, flow cytometry, western blot assay, and xenograft model. The reversible analogue of SKLB-03220 (SKLB-03224) was used as negative control.

Results

1. SKLB-03220 were covalently bound with EZH2 protein

Fig. 1 Mass spectra of EZH2 protein (SET) preincubated with SKLB-03220.

Fig. 2 Predicted binding mode of SKLB-03220 (yellow stick) with EZH2.

2. Inhibitory activity of SKLB-03220 on EZH2WT and EZH2MUT

Fig. 3 Potency of SKLB-03220 and reversible analogs SKLB-03224 against EZH2WT(A) and EZH2MUT(B).

3. SKLB-03220 inhibited the cell proliferation in ovarian cancer cells

Fig. 4 Proliferation inhibitory effect of SKLB-03220 and reversible analogs SKLB-03224 against Ovarian cancer cell lines A2780 and PA-1.

4. SKLB-03220 induced apoptosis of ovarian cancer cells

Fig. 5 SKLB-03220 induced apoptosis of PA-1

5. SKLB-03220 inhibited the expression of H3K27me3

Fig. 6 SKLB-03220 inhibited the expression of H3K27me3 in A2780 and PA-1.

6. Washout experiments confirmed SKLB-03220 is covalent inhibitor

Fig. 7 Cellular washout experiments confirmed SKLB-03220 is covalent inhibitor

7. SKLB-03220 inhibited tumor growth in PA-1 xenograft animal model

Fig. 8 SKLB-03220 was more effective in reducing the growth of PA-1 xenograft animal model than EPZ6438

Conclusion

Taken together, SKLB-03220 is a potent, selective EZH2 covalent inhibitor with noteworthy potency against ovarian cancer both in vitro and in vivo.

This work was supported by the National Natural Science Foundation of China (82073687), the Science and Technology of Sichuan Province (2020YFS0311, 2021YFH0145), and Excellent Youth Fund of Sichuan Cancer Hospital (YB2021024). Please contact Yongxia Zhu (zhuyongxia0409@163.com) if you have any questions.